000			01397 a2200373 4500
005			20250516182718.0
264		0	_c20140731
008			201407s 0 0 eng d
022			_a1873-2518
024	7		_a10.1016/j.vaccine.2013.11.010 _2doi
040			_aNLM _beng _cNLM
100	1		_aOpriessnig, Tanja
245	0	0	_aA commercial vaccine based on PCV2a and an experimental vaccine based on a variant mPCV2b are both effective in protecting pigs against challenge with a 2013 U.S. variant mPCV2b strain. _h[electronic resource]
260			_bVaccine _cJan 2014
300			_a230-7 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aAntibodies, Viral _xblood
650	0	4	_aCircoviridae Infections _xprevention & control
650	0	4	_aCircovirus _xclassification
650	0	4	_aCross Protection
650	0	4	_aPilot Projects
650	0	4	_aRandom Allocation
650	0	4	_aSus scrofa
650	0	4	_aSwine
650	0	4	_aSwine Diseases _xprevention & control
650	0	4	_aViral Vaccines _ximmunology
700	1		_aGerber, Priscilla F
700	1		_aXiao, Chao-Ting
700	1		_aMogler, Mark
700	1		_aHalbur, Patrick G
773	0		_tVaccine _gvol. 32 _gno. 2 _gp. 230-7
856	4	0	_uhttps://doi.org/10.1016/j.vaccine.2013.11.010 _zAvailable from publisher's website
999			_c23301298 _d23301298